Latest Insurance News

Emyria reports strong revenue growth driven by expanded insurer-funded mental health programs, marking a significant step in national access to evidence-based PTSD and treatment-resistant depression care.

Income Asset Management reports a 34% rise in Q1 FY2026 revenue despite uncovering a $3 million fraud involving a former employee, maintaining positive EBITDA and strong client engagement.

FINEOS Corporation Holdings PLC reports solid Q3 2025 results, highlighting revenue growth, operational efficiencies, and a key North American client migration to its SaaS platform, underpinning positive free cash flow expectations for FY25.

Phoslock Environmental Technologies reported a $952,000 operating cashflow deficit in Q3 2025 amid rising legal and logistics expenses, while sales volumes improved and production is set to resume in early 2026.

Insurance Australia Group (IAG) reported strong FY25 results and upgraded its FY26 guidance, reflecting the completed RACQ acquisition and ongoing strategic growth initiatives.

Insurance Australia Group (IAG) has upgraded its FY26 financial guidance following the acquisition of RACQ’s insurance business, projecting stronger premium growth and higher profits.

Imricor Medical Systems made significant regulatory strides with FDA submissions for its MRI-guided cardiac ablation devices and launched NorthStar commercially in Europe, even as it reported increased cash outflows in Q3 CY25.

Credit Clear Limited has agreed to acquire UK debt collector ARC Europe for A$10.9 million, backed by a $20.75 million institutional placement led by Chair Paul Dwyer. The deal aims to accelerate growth by integrating Credit Clear’s digital platform into ARC’s established UK operations.

Pinnacle Investment Management has secured a strategic foothold in Japan’s private markets by acquiring up to 13% of Advantage Partners, complementing its strong FY25 growth and global expansion ambitions.

Alligator Energy Limited has released its comprehensive company constitution, detailing governance, shareholder rights, and director responsibilities under Australian law and ASX rules. This foundational document sets the framework for the company’s operations and compliance.

Mesoblast Limited reports a 69% jump in net revenues from its pioneering cell therapy Ryoncil in Q1 FY2026, propelled by expanded physician adoption and new reimbursement pathways. The company also secures convertible note funding and plans pivotal adult trials.

Connexion Mobility reported a modest 1% revenue increase to $2.9 million in Q1 FY26, while net profit before tax declined 19% due to the absence of prior quarter government incentives. The company is advancing its SaaS platform footprint in US automotive retail and investing strategically in Covertrue Group.